Edwards Lifesciences CORP (EW) — Who Owns This Stock? 13F Breakdown (Q2 2026)

EW ranks #296 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

1343 institutions disclose a position in EW, but none treat it as a major bet — even Wellcome Trust LTD, its most concentrated holder, allocates just 4.8% of its own portfolio to it.

Assenagon Asset Management S.A. has added to its EW position for two straight quarters, increasing it by $133.4M to reach $234.7M today.

Fisher Funds Management LTD has trimmed its EW position for two straight quarters, cutting it by $23.3M while still holding $18.3M.

EW is down 1.7% today, but institutions show net buying of $13.9B this quarter — a divergence between today's price move and the underlying institutional flow.

EW posted net income of $1.0B over the trailing twelve months, and currently trades at a P/E of 50.5.

• Profitable — net income of $1.0B over the trailing twelve months
• Revenue grew 14.6% year over year
• Net income declined year over year, from $4.1B to $1.0B
• Generated $1.6B in positive operating cash flow
• Current ratio of 3.72x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.33x equity — within a conventional range